๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Primary Peritoneal Cancer
Clinical trial register · United States · industry-sponsored

Primary Peritoneal Cancer Trials in the USA

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 9094 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
9094
Studies in scope
industry-sponsored, all four open statuses
4935
Recruiting now
open to new participants
2188
Lead sponsors
across recruiting studies
Top states
California 9 Florida 9 Alabama 6 Illinois 5 Massachusetts 5
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AbbVie3 Regeneron Pharmaceuticals2 Imunon2 Merck Sharp & Dohme LLC1 Genelux Corporation1
State
California9 Florida9 Alabama6 Illinois5 Massachusetts5
All 26 states
Target enrolment
to
11 of 9094 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
NCT07322094FIGO Stage III and IV Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer
TORL Biotherapeutics, LLC
Phase 1/2
60
California, Minnesota, New York, North Carolina
2025-12-10
Recruiting
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRฮฑ)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
NCT06890338Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant
AbbVie
Phase 2
140
Alabama, California, Connecticut, Florida, Illinois, Indiana, Kentucky, Louisiana
2025-11-21
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
NCT06682988Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers
AbbVie
Phase 2
110
Florida, Kentucky, Massachusetts, Michigan, Pennsylvania, Texas
2025-05-28
Recruiting
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
NCT06787612Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Regeneron Pharmaceuticals
Phase 2
297
Alabama, California, Florida, Illinois, Kansas, Kentucky, Massachusetts, Michigan
2025-05-28
Recruiting
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06824467Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Merck Sharp & Dohme LLC
Phase 3
770
Alabama, Alaska, California, Connecticut, Florida, Georgia, Indiana, Louisiana
2025-04-09
Recruiting
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT05739981Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Imunon
Phase 1/2
30
Maryland, New York, Oklahoma, Texas
2023-02-10
Active, closed
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRฮฑ) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
NCT05456685High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
AbbVie
Phase 2
125
Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana, Massachusetts
2022-09-28
Recruiting
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
NCT05281471Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Genelux Corporation
Phase 3
186
Alabama, Arizona, California, Florida, Georgia, Indiana, Maryland, Michigan
2022-08-31
Recruiting
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT04657068Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Artios Pharma Ltd
Phase 1/2
542
Alabama, Arizona, Arkansas, California, Colorado, Florida, Illinois, Indiana
2021-01-27
Recruiting
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
NCT04590326Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
Regeneron Pharmaceuticals
Phase 1/2
612
California, Florida, Illinois, Massachusetts, Michigan, New York, Ohio, Pennsylvania
2020-12-08
Active, closed
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
NCT03393884Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Imunon
Phase 1/2
130
Alabama, California, Florida, Massachusetts, Missouri, New Jersey, New York, Oklahoma
2018-09-05
Rows per page Showing 1–11 of 11
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 September 2026. https://priyalifescience.com/clinical-trials-usa/condition/primary-peritoneal-cancer

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.